Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
Clene Inc. plans to submit a New Drug Application (“NDA”) for lead candidate CNM-Au8® in ALS by year-end 2025. FDA meetings scheduled in Q3 2025 will address ALS survival benefit data and MS development plans. Neurofilament light biomarker data analysis from the NIH-sponsored EAP program is expected in early Q4 2025. The company reported $7.3 million in cash and cash equivalents as of June 30, 2025, together with recent financing extending the company’s cash runway into Q1 2026. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and…







